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Abstract
With confirmed coronavirus disease 2019 (COVID-19) cases surpassing the 18 million mark around the globe, there is an
imperative need to gain comprehensive understanding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Although the main clinical manifestations of COVID-19 are associated with respiratory or intestinal symptoms, reports of
neurological signs and symptoms are increasing. The etiology of these neurological manifestations remains obscure, and
probably involves several direct pathways, not excluding the direct entry of the virus to the central nervous system (CNS)
through the olfactory epithelium, circumventricular organs, or disrupted blood–brain barrier. Furthermore, neuroinflamma-
tion might occur in response to the strong systemic cytokine storm described for COVID-19, or due to dysregulation of the
CNS rennin-angiotensin system. Descriptions of neurological manifestations in patients in the previous coronavirus (CoV)
outbreaks have been numerous for the SARS-CoV and lesser for Middle East respiratory syndrome coronavirus (MERS-
CoV). Strong evidence from patients and experimental models suggests that some human variants of CoV have the ability to
reach the CNS and that neurons, astrocytes, and/or microglia can be target cells for CoV. A growing body of evidence shows
that astrocytes and microglia have a major role in neuroinflammation, responding to local CNS inflammation and/or to
disbalanced peripheral inflammation. This is another potential mechanism for SARS-CoV-2 damage to the CNS. In this
comprehensive review, we will summarize the known neurological manifestations of SARS-CoV-2, SARS-CoV and MERS-
CoV; explore the potential role for astrocytes and microglia in the infection and neuroinflammation; and compare them with
the previously described human and animal CoV that showed neurotropism to propose possible underlying mechanisms.
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The coronavirus disease 2019 (COVID-19) was originat-
ed in Wuhan, China in December 2019, and the etiolog-
ical agent was named severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). The outbreak quickly
turned into a global pandemic with more than 18 million
reported cases around the globe and more than 700,000
deaths (World Health Organization [WHO] Report
COVID-19). The SARS-CoV-2 outbreak is not the first
coronavirus (CoV) epidemic to emerge in the 21st centu-
ry: Both the 2002 SARS-CoV and the 2012 Middle East
respiratory syndrome coronavirus (MERS-CoV) have
been included in this classification. Compared with
other CoV (HCoV-229E, HCoV-OC43, HCoV-NL63),
that are pathogenic to humans but present only mild
clinical symptoms, SARS-CoV-2 resembles both
MERS-CoV and SARS-CoV in their potential to cause
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a more severe disease and also in the fact that they are
able to infect both the upper and lower respiratory tract
(Lu et al., 2020b). Most COVID-19 patients present mild
signs, or even show asymptomatic disease progression.
The main clinical symptoms are fever, dry cough, fatigue,
and dyspnea (Yang et al., 2020a).
A mounting body of reports from SARS-CoV-2-
affected patients is showing that about 30% to 40% of
patients develop serious central nervous system (CNS)
symptoms, with neurological and neuroradiological alter-
ations confirmed in a large number of cases (Alam et al.,
2020; Helms et al., 2020; Jasti et al., 2020; Kremer et al.,
2020; Mao et al., 2020; Najjar et al., 2020; Pryce-Roberts
et al., 2020; Román et al., 2020; Romero-Sánchez et al.,
2020; Xiong et al., 2020; and several others). Plasma bio-
markers of CNS injury have been shown to be increased in
a group of patients with moderate and severe COVID-19
disease (Kanberg et al., 2020). The finding of viral anti-
gens, viral genomic sequences or specific antibodies
against SARS-CoV-2 in cerebrospinal fluid (CSF) is less
common; however, the contribution of diagnostic compli-
cations (i.e., false-negative results) or insufficient CSF viral
load to be detected by real-time polymerase chain reaction
should not be excluded (Benameur et al., 2020; Moriguchi
et al., 2020; Najjar et al., 2020; Virhammar et al., 2020;
Wu et al., 2020).
Intensive research during the past two decades has
demonstrated that CNS neurons would not be able to
survive without the support of glial cells in matters of
metabolic balance, energy supply, immune response,
and even effective neurotransmission. We now recognize
that astrocytes are complex, heterogenic glial cells that
encompass several important and versatile functions that
include maintenance of CNS homeostasis, structural and
metabolic support, modulation of synaptogenesis and
synaptic transmission, participation in immune response
in cooperation with microglia, regulation of blood flow,
and maintenance of the blood–brain barrier (BBB;
reviewed in Barres, 2008; Sofroniew and Vinters, 2010;
Clarke and Barres, 2013; Ramos, 2016; Zorec et al.,
2019). When astrocytes sense stimuli associated to
injury or disease, including viral infection, they respond
with a process called astrogliosis that profoundly alters
astrocytic biology. Reactive gliosis is a fine graded and
highly conserved mechanism of astroglial response to
injury, and, in general terms, it is supposed to be aimed
to improve neuronal survival, to restore BBB, and to
isolate the injured area by providing glial scar formation
(Sofroniew and Vinters, 2010; Anderson et al., 2016;
Verkhratsky et al., 2019). However, under certain not
yet completely defined circumstances, but probably
involving proinflammatory microglial activation and
toll-like/NF-jB/STAT3-dependent pathways, astrocytes
may engage into a proinflammatory gene expression pro-
gram also called maladaptive reactive astrogliosis that
transforms astrocytes into proinflammatory and proneur-
odegenerative cells (Pekny et al., 2016; Liddelow et al.,
2017; Rosciszewski et al., 2018, 2019; Zorec et al., 2019).
Transcriptomic analyses of reactive astrocytes have also
identified this spectrum of possible activation profiles rang-
ing between two extreme phenotypes that were simplisti-
cally defined as the proinflammatory proneurodegenerative
A1 phenotype and the proneuronal survival immunomod-
ulatory A2 phenotype, but these studies also showed mixed
reactive profiles characterized by the expression of PAN-
reactive genes (Hamby et al., 2012; Zamanian et al., 2012;
Anderson et al., 2016; Burda and Sofroniew, 2017;
Liddelow and Barres, 2017; Liddelow et al., 2017; Clarke
et al., 2018). Intensive research from our group and others
has shown that astroglial engagement in the
proinflammatory-neurodegenerative gene expression pro-
gram is facilitated by astroglial exposure to pathogen-
associated molecular patterns (PAMP), damage-associated
molecular patterns (DAMP), and to microglial-derived
proinflammatory cytokines (Rothhammer et al., 2016;
Liddelow et al., 2017; Rosciszewski et al., 2018, 2019). It
is also proposed that persisting reactive gliosis, as shown in
neurodegenerative diseases, as well as infectious agents
reaching the CNS, facilitate the proinflammatory program
in reactive astrocytes (reviewed in Pekny et al., 2016; Zorec
et al., 2019).
Microglia are the professional immune cells in the
CNS and thus are the first responders to brain injury
or infection. However, current knowledge shows that
microglia are also a highly heterogeneous cell population,
with sex- and region-specific differences that exert a
plethora of physiological roles in healthy CNS including
patrolling of brain parenchyma, clearing apoptotic cells
and other debris, regulating neuronal plasticity by par-
ticipating in synaptic pruning, and responding to signals
from peripheral immune system (Wilton et al., 2019;
Ewald et al., 2020; Gerrits et al., 2020). Following CNS
viral infection, microglial cells become rapidly activated
and release proinflammatory molecules and reactive
oxygen species, recruit cells of the peripheral immune
system, and activate astrocytes (Ransohoff and Perry,
2009; Chatterjee et al., 2013; Wheeler et al., 2018).
Previous experiences with SARS-CoV and MERS-
CoV, as well as experimental data on neurotropic
CoVs, have shown that CoV can reach the CNS and
infect it (Steardo et al., 2020). We here performed a com-
prehensive review on the CNS cell types known to be
affected by CoV infections with a special focus on the
role of astrocytes and microglia and the consequences for
brain physiology.
Middle East Respiratory Syndrome
MERS-CoV has been identified as a cause of severe respi-
ratory infection in humans since the 2012 outbreak, being
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the second highly pathogenic CoV to rapidly spread
into human populations. The number of laboratory-
confirmed cases reported by the WHO until January
2020 was of 2,519 cases globally, with a mortality rate
of 34.3% (WHO, 2019). Although the MERS-CoV infec-
tion was asymptomatic in some patients, many cases pre-
sent pneumonia and severe symptoms that can result
in multiorgan failure and death (WHO MERS-CoV
Research Group, 2013).
There are a number of reports of MERS-CoV patients
showing neurological symptoms (Arabi et al., 2015; Kim
et al., 2017), although the overall number of reports
showing neurological manifestations in MERS patients
is low compared with the present knowledge on SARS-
CoV-2. However, MERS-CoV belongs to lineage C of
the genus Betacoronavirus, whose species are known to
be potentially neuroinvasive (Desforges et al., 2014).
Reported neurological symptoms in MERS-CoV infec-
tion mostly come from case reports, and findings include
neuropathy, delirium, and seizures (Saad et al., 2014;
Arabi et al., 2015; Algahtani et al., 2016; Kim et al.,
2017). However, the number of reports is quite low prob-
ably due to the significant comorbidities and the severe
critical condition of complicated MERS-CoV patients.
In spite of their similarity, MERS-CoV does not share
with SARS-CoV and SARS-CoV-2 the mechanism to
gain access to cells. MERS-CoV utilizes exopeptidase,
dipeptidyl peptidase 4 (DPP4), as a receptor to enter
host cells. Human DPP4 (hDPP4) expression is a require-
ment to make nonsusceptible species, such as rodents,
become susceptible to MERS-CoV infection (van
Doremalen and Munster, 2015). MERS-CoV has also
shown increased mortality in obese patients, and the find-
ing has been related to increased expression of DPP4 in
obese people (Al-Hameed, 2017).
MERS-CoV has the potential ability to enter micro-
glia, astrocytes, and neurons, considering that all these
cell types express DPP4 (Király et al., 2018; Elkjaer et al.,
2019). Among these CNS cells, glial fibrillary acidic
protein-positive (GFAPþ) astrocytes seem to show the
largest DPP4 basal expression, and inflammation signif-
icantly increased the expression of the viral receptor
(Király et al., 2018), thus allowing a feed-forward loop
that increases MERS-CoV access to glial cells. Moreover,
DPP4 was also found in brain microvasculature (Kenny
and Bourne, 1991; Zeng et al., 2019) turning endothelial
cells into another MERS-CoV potential target.
Studies in transgenic mice expressing hDPP4 or
adenoviral-based expression of hDPP4 in mice have
shown that intranasal exposure to MERS-CoV resulted
in illness and high mortality rates (reviewed in van
Doremalen and Munster, 2015). In these mice, viral
RNA was detected in several organs including lungs
and brain. While dramatic lesions were found in the
lungs of these hDPP4-expressing mice, no gross
pathological changes were observed in the brain; howev-
er, viral antigen expression was found in brain microglia,
astrocytes, and neuronal cells, together with increased
proinflammatory cytokines and chemokines (Agrawal
et al., 2015; Zhao et al., 2015; Tao et al., 2016). Indeed,
Tao et al. (2016) were able to recover viral particles from
brain tissue and detected viral antigen expression in neu-
rons and glia of the hDPP4 mice. In silico modeling of
common marmoset DPP4 showed high similarity with
hDPP4, and, as was predicted, this resulted in high sus-
ceptibility of marmosets to MERS-CoV (Raj et al., 2013;
Falzarano et al., 2014). Infected marmosets showed
severe illness, and viral RNA was detected in all tested
organs including lungs and brain (van Doremalen and
Munster, 2015). There is, however, another report using
transgenic hDPP4 mice that found no evidence of
MERS-CoV viral infection in the brain, although these
authors used a hDPP4 promoter that rendered negative
hDPP4 expression in neurons and glia (Iwata-Yoshikawa
et al., 2019).
Among the MERS-CoV patient case reports describ-
ing neurological symptoms (Saad et al., 2014; Arabi
et al., 2015; Algahtani et al., 2016; Kim et al., 2017), it
is interesting to note that MRI findings obtained by
Arabi et al. (2015) were rather supportive of primary
viral neuropathology resembling an acute disseminated
encephalomyelitis (Marin and Callen, 2013). The study
lacks, however, a confirmatory test for brain infection,
such as could have been the positive detection of MERS-
CoV in brain tissue or CSF (Arabi et al., 2015).
Taken together, the published evidence shows that we
still lack confirmatory studies demonstrating the presence
of MERS-CoV viral particles in the CNS of human
patients; however, the brain imaging findings (Arabi
et al., 2015), together with clinical findings (Saad et al.,
2014; Arabi et al., 2015; Algahtani et al., 2016; Kim et al.,
2017), are highly indicative of a direct effect of MERS-
CoV on the CNS. Experiments using hDPP4 expression
in animals have shown that MERS-CoV has the ability of
infecting and proliferating in microglia, astrocytes, or
even in neurons (Agrawal et al., 2015; Zhao et al.,
2015; Tao et al., 2016), but this seems to be highly depen-
dent on DPP4 expression in these cell types (Iwata-
Yoshikawa et al., 2019).
Severe Acute Respiratory Syndrome
The first reported outbreak of a human CoV producing
SARS, named SARS-CoV, emerged in November 2002
in Guangdong Province, China. Since then, until the
mysterious disappearance of SARS-CoV cases 6
months later, the outbreak resulted in 8,098 SARS-CoV
cases, with 774 deaths, a 9.56% mortality rate (WHO,
2004). As both the present SARS-CoV-2 and MERS-
CoV, SARS-CoV belongs to the Coronavirinae
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subfamily, genera betacoronaviruses (Ng Kee Kwong
et al., 2020).
SARS-CoV patients usually referred high fever asso-
ciated with chills, headache, muscular pain, and some-
times diarrhea. Most patients develop respiratory
symptoms and pneumonia, with 10% to 20% of the
patients requiring mechanical ventilation.
Several case reports showing neurological symptoms
were documented for SARS-CoV. Among the neurolog-
ical symptoms, the most abundant were those showing an
effect on the CNS such as seizures, dysphoria, vomiting,
and deliria, (Hung et al., 2003; Lau et al., 2004; Tsai
et al., 2005; Xu et al., 2005) as well as stroke
(Umapathi et al., 2004; Xu et al., 2005). In spite of the
low number of patients showing neurological clinical pre-
sentation, the finding of viral RNA in both CSF (Hung
et al., 2003; Lau et al., 2004) as well as in autopsied
human brain tissue (Xu et al., 2005) reflects the potential
neurotropism of SARS-CoV.
Xu et al. (2005) have shown that viral SARS-CoV
proteins were expressed in the brain of a SARS-CoV
patient who presented severe neurological symptoms. In
addition, the authors also recovered infective viral par-
ticles from autopsy brain preparations of this patient.
Brain sections showed an intense inflammation with
CD68þ macrophages infiltration, neuronal necrosis, dif-
fuse brain edema, and reactive gliosis. Moreover, viral
proteins were detected by immunohistochemistry in
brain neurons and astrocytes (Xu et al., 2005).
In a series of patients who died from SARS-CoV
infection, Ding et al. (2004) systematically analyzed the
SARS-CoV presence in different organs, and they found
that the virus was present not only in the respiratory
organs but also in isolated cerebral cortical neurons
(Ding et al., 2004). SARS-CoV particles in cortical and
hypothalamic neurons as well as important signs of neu-
ronal degeneration and brain edema were also detected
by Gu et al. (2005) in a series of patients who died
from SARS.
Interestingly, SARS-CoV isolated from human
patients was shown to be able to infect mice (Glass
et al., 2004; Subbarao et al., 2004), ferrets, domestic
cats, and various species of monkeys (Martina et al.,
2003; Haagmans et al., 2004). After intranasal inocula-
tion, SARS-CoV infection in mice was initially present in
the respiratory tract, then reaching different organs,
including the brain (Glass et al., 2004). Mice brains
showed a large increase of cells with SARS-CoV sequen-
ces, and authors could also isolate infective viral particles
from these mice brains (Glass et al., 2004), in a striking
similarity to the human reported cases (Ding et al., 2004;
Xu et al., 2005). In SARS-CoV-infected mice, viral-
positive cells were predominantly observed in brain hip-
pocampus in the pyramidal cell layer of the hippocampal
CA1 region and in the dentate gyrus (Glass et al., 2004).
In addition, evidence of neuroinflammation was con-
firmed by the elevated cytokine expression in the brains
of SARS-CoV-infected mice (Glass et al., 2004).
SARS-CoV was the first human CoV reported to bind
to human angiotensin-converting enzyme 2 (ACE2) to
infect host cells through interaction with SARS-CoV
spike protein (Li et al., 2003; Prabakaran et al., 2004;
Wang et al., 2004). The ACE2 expression profile was
characterized in detail by Hamming et al. (2004) using
human biopsies (Hamming et al., 2004). As expected,
they found ACE2 expression in the lung alveolar epithe-
lial cells and enterocytes of the small intestine, but they
also found that ACE2 was present in arterial and venous
endothelial cells and arterial smooth muscle cells in all of
the organs studied. Specifically in the brain, the authors
found that ACE2 is expressed in endothelium and vascu-
lar smooth muscle cells (Hamming et al., 2004), while
others later reported ACE2 expression in neurons and
glia (Gallagher et al., 2006; Matsushita et al., 2010;
Gowrisankar and Clark, 2016; Xu et al., 2017; de
Morais et al., 2018). In mice, ACE2 neuronal expression
was described to be present in both areas involved in the
central regulation of cardiovascular function, as well as
in noncardiovascular nuclei (Doobay et al., 2007; Lin
et al., 2008).
SARS-CoV outbreak stopped suddenly; therefore,
studies of human brains from SARS-CoV-infected
patients with CNS symptoms are lacking, and most stud-
ies used the approach of humanizing the ACE2 in mice.
For example, McCray et al. (2007) developed transgenic
mice that express the human ACE2 receptor under the
control of the cytokeratin 18 promoter (K18-hACE2
mice). Intranasal infection of K18-hACE2 mice with
SARS-CoV resulted in a fatal disease, directly related
to the number of copies of hACE2 transgene and
hACE2 mRNA levels (McCray et al., 2007).
Histopathological analysis of these animals showed
extensive virus replication not only in the lungs but
also in the brain (McCray et al., 2007; Tseng et al., 2007).
Netland et al. (2008) performed experiments analyzing
the temporal dynamics of brain infection following intra-
nasal SARS-CoV administration in hACE2 mice. The
authors showed that SARS-CoV N protein was detect-
able and surprisingly widespread in brain regions, and
subsequent viral clearance was associated with neuronal
loss in these areas (Netland et al., 2008). Time course
studies showed a pattern of viral infection that was
strongly suggestive of an entry via the olfactory nerve,
with subsequent transneuronal spreading (Netland et al.,
2008). Netland et al. (2008) did not detect reactive astro-
gliosis in SARS-CoV-infected hACE2 mice. This is sur-
prising when considering that this apparent astroglial
unresponsiveness to viral infection is accompanied by
an increased number of Iba1þ microglia and interleukin
(IL)-6 overexpression, a cytokine that is mainly produced
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by astrocytes and microglia. Moreover, overexpression of
a plethora of proinflammatory cytokines was observed in
the brain of SARS-CoV-infected mice, most notably IL-
6, interferon (IFN)-c, chemokine (C-C motif) ligand
(CCL)-2, and CCL12 (Glass et al., 2004; McCray et al.,
2007; Tseng et al., 2007) and also in cases reported in
humans (Xu et al., 2005). We now know that astrocytes
are highly sensitive to increased proinflammatory media-
tors and that this stimulus induce a proinflammatory
gene expression program in astrocytes (Liddelow and
Barres, 2017; Rosciszewski et al., 2019; Verkhratsky
et al., 2019).
Taken together, the accumulated evidence from
patients who died from severe SARS with CNS compro-
mise as well as the experimental data from wild-type or
transgenic hACE2 animal models show that SARS-CoV
is able to effectively reach and infect CNS cells, express
viral proteins, and produce neurodegeneration. The
hypotheses about the pathways utilized by SARS-CoV
to reach the brain are essentially (a) the olfactory bulb/
transsynaptic pathway or (b) the hematogenous spread
from heavily infected lungs and airways. This latter alter-
native is facilitated by systemic inflammation that
increases BBB permeability and astroglial/microglial
proinflammatory response due to circulating cytokines
and/or due to local viral replication in the CNS.
When analyzing the potential glial role in SARS-CoV
infection, in addition to the possibility that the virus rep-
licates in glial cells, we should also consider the glial role
in the strong neuroinflammatory response that can be
induced by viral invasion or that can be attributed to
the increased peripheral cytokine levels. Astrocytes and
microglia are sensitive to peripheral cytokines, and their
activation and engagement into a proinflammatory gene
expression program could also increase BBB permeabil-
ity. Proinflammatory astrocytes seem to have a main role
in SARS-CoV infection by recruiting peripheral macro-
phages and lymphocytes to the brain parenchyma, thus
increasing edema and cytotoxicity in these conditions
(Xu et al., 2005). Specifically, an increased expression
of IFN-c was found in glial cells of a patient that devel-
oped severe CNS invasion by SARS-CoV (Xu et al.,
2005). In addition, the possibility that SARS-CoV infec-
tion alters the brain microvasculature is likely, either by a
direct effect on the endothelium and glial cells due to
viral invasion, or secondary to the strong inflammatory
response elicited in either human or animal hosts (Glass
et al., 2004; Xu et al., 2005).
Other Human CoV That Show
Neurotropism
CoVs are widely known as human pathogens causing
respiratory tract infections. In addition to SARS-CoV,
MERS-CoV, and SARS-CoV-2, other human CoV
(HCoV) have been described in the past decades, includ-
ing HCoV-229E, HCoV-NL63, HCoV-OC43, and
HCoV-HKU1 (Gaunt et al., 2010; Zlateva et al., 2013;
Desforges et al., 2019).
Although HCoV are usually restricted to the airways
in immunocompetent patients, several studies showed
evidence of neurotropic and neuroinvasive capacities of
some HCoV strains (reviewed in Desforges et al., 2014,
2019). Early findings from Arbour et al. (2000) have
shown a high prevalence of HCoV-229E and HCoV-
OC43 in human brain autopsy samples of patients affect-
ed with multiple sclerosis and other neurological
diseases (Arbour et al., 2000). In addition, neurological
symptoms have been described in association with both
HCoV-HKU1 and HCoV-NL63 infections (Severance
et al., 2011).
Experimental studies have shown that HCoV strains
have the ability of replicating in glial cells in vitro. In fact,
the HCoV-229E and HCoV-OC43 have shown to infect
glial and neuronal cell lines as well as primary human
astrocytic cultures (Bonavia et al., 1997; Arbour et al.,
1999a, 1999b; Jacomy et al., 2006). In vivo, HCoV-OC43
is naturally neuroinvasive and promotes chronic enceph-
alitis in mice, with clustering of microglial cells and neu-
ronal loss (Jacomy et al., 2006).
Taken together, the present data point out to a neuro-
invasive potential of HCoV-OC43 and HCoV-229E,
where astrocytes, microglia, and/or neurons could be
the cell targets of the infection (Malone et al., 2006;
Hwang and Bergmann, 2018). Again, the potential
routes for HCoV are the hematogenous spread during
viremia or the retrograde neuronal route (revised in
Desforges et al., 2019).
In general terms, microglia and astrocytes play a crit-
ical role in RNA virus infection (Soung and Klein, 2018).
The HIV is another RNA virus of great importance in
public health where neurotropism, and especially the glial
role in infection and chronicity, is being rapidly unveiled.
HIV-1 exploits the Trojan Horse Strategy to reach the
CNS parenchyma, where infected T cells and monocytes
cross the BBB, transferring infection to microglia and
CNS perivascular macrophages (González-Scarano and
Martın-Garcıa, 2005; Elbirt et al., 2015). While macro-
phages and microglia exhibit productive infection and
can release viral particles, astrocytes become infected,
but they show restricted HIV-1 replication and nonpro-
ductive infection (reviewed in Churchill and Nath, 2013;
Zorec et al., 2019). However, this is a double-edged sword;
on one hand, nonproductive astroglial infection reduces
brain damage, which would be otherwise a devastating
CNS disorder, but on the other hand, it allows for HIV-1
to latently persist in the brain parenchyma even in suc-
cessfully treated patients with low viral load (reviewed in
Pandey and Seth, 2019). Moreover, in patients with HIV-
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associated dementia, more than 19% of astrocytes have
HIV sequences, and the abundance is higher in astrocytes
that are in close proximity to macrophages, especially at
the perivascular regions (Churchill et al., 2009; reviewed
in Pandey and Seth, 2019). In addition, it is not clear how
viral persistence affects the normal homeostatic functions
of astrocytes that are essential for the CNS functionality.
Surviving, but persistently infected astrocytes could be
suffering a pathological remodeling or an astrogliopa-
thology that reduces the neuronal-supportive pathways
that sustain CNS homeostasis.
Animal CoV That Show Neurotropism
HCoV are molecularly and structurally related to several
neuroinvasive animals CoV. Specifically, mouse hepatitis
virus (MHV) has been extensively studied, and both the
John Howard Muller MHV (JHM-MHV) and the MHV-
A59 strain, when inoculated intracranially or intranasal-
ly, are neurovirulent (Bender and Weiss, 2010; Cowley
and Weiss, 2010). In general terms, after nasal inocula-
tion, neurotropic strains of MHV reach the CNS through
a transneuronal route up to the olfactory bulbs, from
where viral particles spread into the brain parenchyma
(Perlman et al., 1990; revised in Cowley and Weiss, 2010).
In rats, MHV infection promotes a primary stage of
neuronal and glial infection, severe inflammation, and
destructive lesions mainly in the gray matter, followed
by a secondary stage of demyelination with chronic
inflammation, astrogliopathology with astroglial loss
and axonal pathology (Nagashima et al., 1978, 1979;
Zimprich et al., 1991).
Since the JHM-MHV strain is highly lethal in mice, a
larger number of studies have been performed using the
sublethal glia tropic variant of the JHM-MHV, desig-
nated v2.2-1 (Savarin and Bergmann, 2018). Both suble-
thal MHV-59 and JHM-MHV v2.2-1 viruses are able to
produce an acute encephalomyelitis that turns into a per-
sistent infection causing demyelinating lesions with pres-
ence of viral RNA, but absence of infective viral particles
(Savarin and Bergmann, 2018). Infection of Lewis rats
with JHM-MHV CoV induces viral particle incorpora-
tion by astrocytes and reactive astrogliosis at the sur-
roundings of demyelinated lesion plates (Barac-Latas
et al., 1997).
The murine JHM-MHV strain was shown to infect
astrocytes in vitro and in vivo, and astrocytes apparently
constitute a viral reservoir in asymptomatic JHM-MHV-
infected mice (Perlman and Ries, 1987). These early
reports are consistent with the hypothesis that astrocytes
can not only be hosts of the CoV but can also behave as
reservoirs of CoV in the brain parenchyma. In culture,
MHV infects astrocytes and microglia promoting a
proinflammatory conversion of both cell types evidenced
by an increase in proinflammatory cytokines such as
tumor necrosis factor (TNF)a, IL-1b, and IL-6. Such
phenomenon has been also evidenced in vivo during
encephalitis and demyelination of spinal cord in mice
models (Sun et al., 1995; Gonzales et al., 2004; Li
et al., 2004). Moreover, following intranasal inoculation
with JHM-MHV, microglia become rapidly activated;
release proinflammatory IL-6, TNFa, and IFN-a/b;
phagocytize infected cells; and recruit peripheral mono-
cytes/macrophages by secreting the chemokine CCL2
(Wheeler et al., 2018). This major role of microglia in
the primary response to JHM-MHV CoV is supported
by the fact that microglial depletion exacerbated viral
replication and dissemination in the mice brain
(Wheeler et al., 2018).
The less aggressive JHM-MHV variant v2.2-1 also
infects microglia, astrocytes, and oligodendrocytes.
Here, major histocompatibility class I and II complexes
are upregulated in microglial cells and astrocytes in
response to IFNc, while oligodendrocytes may serve as
a reservoir for viral persistence (Suzumura et al., 1986;
Malone et al., 2006).
After intranasal exposure in mice, MHV-A59 produ-
ces acute hepatitis, meningitis, and encephalitis followed
by a chronic phase of inflammatory demyelinating dis-
ease. It is clear that the acute phase involves active viral
replication in liver and brain, while in the chronic phase,
viral RNA persist in the brain, but without evidence of
viral replication or viral antigen expression (Lavi and
Cong, 2020). Infection with MHV-A59 induces upregu-
lation of several proinflammatory cytokines in astrocytes
as well as the IFNa, IFNb, and IFNc (Lavi and Cong,
2020). On the other hand, the same authors showed that
in microglia, MHV-59 induces the expression of IL-6 and
of all the members of the IFN and TNF family.
Interestingly, the nonencephalitic MHV strain (MHV-
2), that does not produce acute or chronic encephalitis,
failed to induce cytokine expression in astroglial or
microglial cultures (Lavi and Cong, 2020). These impor-
tant findings reinforce the concept that engagement of
reactive astrocytes and microglia in a proinflammatory
response is a key event in CoV infections. The downside
of this activation is the neural detrimental effects of such
proinflammatory environment that may contribute to
cognitive impairments in neurotropic CoV infections. In
agreement, the fine tuning of the cytokine storm in these
CoV infections with anti-inflammatory cytokines or reg-
ulatory T-cells (Tregs) adoption reduces secondary demy-
elinating lesions (Trandem et al., 2010; Blanc et al., 2014;
Savarin and Bergmann, 2018).
However, the switch to a proinflammatory gene
expression program seems not to be the unique astroglial
and microglial response to neurotropic virus, and espe-
cially to neurotropic CoV. Astrocytes and microglia are
the CNS-resident cells most prominently involved in the
innate immunity responses, as they are able to respond to
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PAMP that interact with pattern recognition receptors
highly expressed in microglia and also expressed in lower
level in astrocytes (Farina et al., 2007; Russo and
McGavern, 2015; Hwang and Bergmann, 2018;
Rosciszewski et al., 2018, 2019). Recent findings have
shown that astrocytes mount a delayed but robust antivi-
ral response to the neurotropic MHV-A59 CoV in vivo in
the rodent encephalitis model (Hwang and Bergmann,
2018). In this model, astrocytes upregulated the IFN-a/b
pathway to a greater extent than microglia.
Concomitantly, the specific ablation of interferon-a/b
receptor (IFNAR) in astrocytes using a transgenic
mGFAPcre IFNARfl/fl mice resulted in severe encephalo-
myelitis, increased neutrophil and decreased T-cell infiltra-
tion, uncontrolled viral spread in the CNS parenchyma,
and increased lethal effects in deficient mice (Hwang and
Bergmann, 2018). As mentioned before, IFNc, one of the
type 2 interferons (IFN-II), is a key molecule in the
response of glial cells to viral infection, and it is produced
by cells that are not brain residents. However, type 1
interferons (IFN-I) and the astroglial IFNAR also play
a major role in responses to neurotropic viral infection,
including CoV (Malone et al., 2006; Owens et al., 2014;
Hwang and Bergmann, 2018).
In addition to the astroglial role in preventing CNS
spreading of MHV-A59, microglia seem also to be
required to control neurotropic CoV infection. A recently
published article showed that depletion of microglia
using PLX5622, an inhibitor of colony-stimulating
factor 1 receptor (CSF1R), in animals exposed to
JHM-MHV increased mortality, impaired control of
viral replication, altered CD4þ and CD8þ T-cell infiltra-
tion, increased demyelination, and decreased neuro-
repair (Mangale et al., 2020).
The Janus-faced astroglial and microglial role in neu-
rotropic CoVs infection, with a required suppressive
effect on CoV replication, but a proinflammatory detri-
mental role in the demyelinating late phase, highlights the
importance of a timely control of the cytokine storm in
CoV infections. These lessons should be critically consid-
ered when developing novel clinical approaches to pre-
vent neurological complications in COVID-19 patients
(see later).
Severe Acute Respiratory Syndrome-2
While the hallmarks of COVID-19 moderate clinical pre-
sentation are fever, respiratory symptoms including dry
cough and dyspnea, and diarrhea, a more severe respira-
tory condition termed acute respiratory distress syndrome
can eventually develop, and it includes the cytokine
release syndrome (cytokine storm). Neurological mani-
festations of SARS-CoV-2 infection are starting to be
systematically recorded and reported, with several initia-
tives to consolidate and record clinical findings
(Ferrarese et al., 2020; Román et al., 2020; Romero-
Sánchez et al., 2020). Between 30% and 40% of the
SARS-CoV-2 patients present neurological symptoms;
these can go from mild symptoms including olfactory
and gustatory disorders, dizziness, headache, confusion,
to a more severe cerebrovascular disease, encephalitis,
seizures, or the Guillain–Barre syndrome (Asadi-Pooya
and Simani, 2020; Kremer et al., 2020; Mao et al., 2020).
The presence of SARS-CoV-2 viral particles in the CNS
has been evidenced in some cases (Benameur et al., 2020;
Moriguchi et al., 2020; Wu et al., 2020), with reports
showing SARS-CoV-2 presence in CSF (Finsterer and
Stollberger, 2020). Other authors also found SARS-
CoV-2 viral particles in neural and capillary endothelial
cells of frontal lobe brain sections of a COVID-19 patient
(Paniz-Mondolfi et al., 2020), while the plasma bio-
markers of CNS damage GFAP and neurofilament
light chain have been shown to be increased in a group
of moderate and severe COVID-19 cases (Kanberg et al.,
2020). In several patients, SARS-CoV-2 infection has
been associated with ischemic stroke, and this has been
originally attributed to excessive inflammation, hypoxia,
or diffuse intravascular coagulation (Lu et al., 2020a;
Mao et al., 2020; Yang et al., 2020b), but a SARS-
CoV-2 direct role in these clinical presentations is
also possible.
SARS-CoV-2 is a single-stranded positive-sense RNA
virus sharing 79% and 50% identity with SARS-CoV
and MERS-CoV, respectively (Lu et al., 2020b). The
spike (S) protein of CoV is known to engage cell surface
receptors to facilitate viral entry into the cells. It has been
determined, as seen for SARS-CoV, that SARS-CoV-2
spike S protein also uses ACE2 as entry receptor
(Hoffmann et al., 2020). Taking into account that
SARS-CoV-2 shares the ACE2-mediated mechanism of
entrance to the cells, it is highly possible that these molec-
ular mechanisms would also help explain the more severe
forms of the disease, including the possibility of a disba-
lanced renin-angiotensin system (RAS), as was demon-
strated for SARS-CoV (Imai et al., 2005; Kuba et al.,
2005; see later).
There are several hypotheses as to how could SARS-
CoV-2 reach and affect the CNS. Neuronal retrograde
dissemination has been observed in other CoV (see ear-
lier), and taking into account the presence of the virus in
nose swabs, hyposmia symptoms in some patients, and
the expression of ACE2 in the nasal mucosa (Hou et al.,
2020), a transneuronal pathway involving olfactory epi-
thelium>olfactory bulb>olfactory nucleus in the pyri-
form cortex cannot be ruled out (Figure 1). In addition,
other authors proposed that SARS-CoV-2 could be
reaching the CNS using the vagus nerve traveling
through lung–gut–brain axis (Alam et al., 2020).
Another possible way for SARS-CoV-2 to enter the
CNS is the hematogenous route during viremia in
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severe affected patients. SARS-CoV-2 could enter
through the circumventricular organs, which lack BBB,
or through altered BBB where endothelial cells and astro-
glial end-feet could have a major role (Figure 1).
Endothelial cells express ACE2 and are thus potential
targets to be infected by SARS-CoV-2 (Hamming et al.,
2004; Feng et al., 2010b). Although there is no present
data of SARS-CoV-2 presence in astrocytes, increased
level of soluble GFAP in plasma of COVID-19 patients
has been reported (Kanberg et al., 2020), and a large
body of data support that astrocytes are target of neuro-
tropic CoV as commented in the previous sections (Sun
et al., 1995; Gonzales et al., 2004; Li et al., 2004; Xu
et al., 2005; Jacomy et al., 2006; Desforges et al., 2019;
Steardo et al., 2020; Figure 2).
In addition to being potential targets for SARS-CoV-
2, both astrocytes and microglia are highly sensitive to
systemic proinflammatory cytokines (Perry et al., 2007;
Teeling and Perry, 2009; Murta et al., 2015; Murta and
Ferrari, 2016). Indeed, the massive release of inflamma-
tory cytokines described for severe COVID-19 patients
could be enough to destabilize the tight junctions of the
BBB endothelial cells and astrocytes, thus facilitating
viral entry (Li et al., 2015; Swanson and McGavern,
2015; Figure 2). Furthermore, as explained in the earlier
sections, astrocytes and microglia are part of the local
neuroinflammatory response of the CNS and express pat-
tern recognition receptors, the cellular receptors needed
to initiate and/or amplify innate immune responses
within the CNS (Farina et al., 2007; Russo and
McGavern, 2015; Hwang and Bergmann, 2018;
Rosciszewski et al., 2018, 2019). As part of the BBB,
astrocytes would rapidly receive the proinflammatory sig-
nals from endothelial cells, in addition to microglial-
derived cytokines. Microglia have been demonstrated to
closely interact with monocytes and lymphocytes in viral
infections affecting the CNS (see, e.g., Hwang and
Bergmann, 2018; Mangale et al., 2020). Moreover, it
has been shown that the presence of reactive proinflam-
matory microglia, the exposure to proinflammatory cyto-
kines such as IL-1b, TNFa, and IL-6, or the exposure to
PAMP/DAMP can induce in astrocytes the expression of
proinflammatory genes that facilitates neuroinflamma-
tion and neurodegeneration (Liddelow et al., 2017;
Rosciszewski et al., 2018, 2019; Figure 2).
As commented in the previous sections, microglial
cells are highly heterogenic and have a plethora of func-
tions in the healthy CNS that are likely to be affected by
the SARS-CoV-2 entrance to the brain, or by the cyto-
kine storm originated in the periphery. This line of
reasoning allowed some authors to propose that SARS-
CoV-2-induced proinflammatory microglial phenotype
might contribute to the development of neurodegenera-
tive disorders (Alam et al., 2020; Mahalaxmi et al., 2020).
Furthermore, the proinflammatory priming of microglia
achieved by the direct SARS-CoV-2 infection, or by the
peripheral cytokine storm, could contribute to the devel-
opment of neuropsychiatric symptoms (Lavi et al., 2020)
or to exacerbate previous clinical or even subclinical signs
and symptoms of neurodegenerative diseases.
The clinical relevance of the RAS in cardiovascular
function has been well established. Angiotensin II (Ang
II), acting through type 1 receptor (ATR1), promotes
vascular contractility, inflammation, and oxidative
Figure 1. SARS-CoV-2 Potential Entry Routes to the CNS. SARS-CoV-2 may reach CNS using two main routes: the olfactory epithelium
or the hematogenous (blood) routes. When entering through the olfactory epithelium, viral particles would have access to the CNS using
transneuronal/synaptic pathways. Following neuronal infection, viral particles released may infect microglia and astrocytes. In the hema-
togenous entry route, endothelial cells may become infected, followed by perivascular astrocytes and perivascular macrophages.
Secondarily, viral particles may reach microglia and neurons. Also during viremia in severe affected patients, SARS-CoV-2 can reach choroid
plexus and circumventricular organs, which lack of BBB, and subsequently entering to brain parenchyma. A third possibility of CNS
infection may arise after BBB breakdown as a consequence of systemic inflammation and cytokine release. Increased BBB permeability
could facilitate SARS-CoV-2 entrance to the CNS.
SARS-CoV-2¼ severe acute respiratory syndrome coronavirus 2; CNS¼ central nervous system; CSF¼ cerebrospinal fluid; BBB¼ blood–
brain barrier.
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stress, while Angiotensin (1–7) (abbreviated as Ang
(1–7)), produced by ACE2, activates mitochondrial
assembly receptor receptors (MasR) counteracting the
effects of the Ang II/AT1R axis (Feng et al., 2008,
2010a, 2010b). As described in previous sections,
SARS-CoV-2 and its predecessor SARS-CoV exploit
the ACE2 receptor to enter to host cells, and it is pro-
posed that decreased ACE2 level occurs in COVID-19
patients. This fact may justify the severe complications
in patients with hypertension, diabetes, and cardiovascu-
lar disease (Abbasi Pashaki et al., 2020; Gan et al., 2020;
and others). Specifically in the brain, Ang (1–7)/MasR
pathway favors vasodilatation, anti-inflammation, anti-
oxidant, and antiapoptotic pathways (reviewed in Xia
and Lazartigues, 2008; Arroja et al., 2016; Abiodun
and Ola, 2020). Since Ang II and Ang (1–7) have oppos-
ing effects, and ACE2 catalyzes the conversion of Ang II
into Ang (1–7), the role of ACE2 in the maintenance of
brain RAS equilibrium is critical. Showing some regional
and anatomical variations, and being enriched in cardio-
vascular regulatory regions of the brain, all RAS compo-
nents are present in the brain (Sriramula et al., 2017; Xu
et al., 2017; de Morais et al., 2018). Astrocytes are the
main source of angiotensinogen and express ATR1 and
MasR; neurons express ATR1, ACE2, and MasR, and
microglia respond to ATR1 activation (Shi et al., 2014;
de Morais et al., 2018). Indeed, the brain is the organ
with the highest MasR expression, and high Ang (1–7)
concentrations have been detected in the brain (Huber
et al., 2017). ACE2 is expressed in brain endothelium,
neurons, and probably in glial cells (Hamming et al.,
2004; Gallagher et al., 2006; Matsushita et al., 2010;
Gowrisankar and Clark, 2016; Xu et al., 2017; de
Morais et al., 2018). The proposed SARS-CoV-2-
Figure 2. Potential Astroglial and Microglial Roles in SARS-CoV-2 Infection.
Astrocytes and microglia are viral hosts: Perivascular astrocytes may incorporate viral particles by direct contact with infected endothelial
cells. However, BBB breakdown may also lead to viral infection of nonperivascular astrocytes and microglia. In both situations, infected
cells may act as viral hosts giving nonproductive infection with mild inflammatory response and with microglia acting as antigen-presenting
cells; or astrocytes may give rise to a productive infection, with destruction of astroglial network. This latter possibility is more unlikely
based on clinical findings.
Astrocytes and microglia are not viral hosts: Astrocytes and microglia are not primary targets of viral infection, but they are responsive to
proinflammatory signals from endothelial cells, macrophages, and/or neurons. In such case, astrocytes and microglia may engage in a
proinflammatory gene expression program that would expand neuroinflammation. This maladaptive reactive astrogliosis would reduce
neuroprotective and metabolic support to neurons which secondarily may degenerate by lack of nutrients and neurotrophic factors.
A¼ astrocytes; M¼microglia; N¼ neurons.
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induced depletion of ACE2 has the potential to induce
severe consequences in brain RAS system by altering the
ATR1/MasR balance toward the neuroinflammation.
For example, ATR1 activation on microglia activates
NF-jB and the release of proinflammatory cytokines
(Shi et al., 2014; de Morais et al., 2018) that may
induce subsequent astroglial proinflammatory response
(Figure 3). Indeed, reduced activity of the Ang (1–7)/
MasR pathway would decrease the antioxidant and
anti-inflammatory mediators in the brain parenchyma
(Figure 3). In fact, brain RAS has been involved in seiz-
ures and epilepsy where hyperactivation of Ang II/ATR1
signaling in astrocytes and microglia have been observed
(Krasniqi and Daci, 2019). Reduced brain blood flow
and ischemia are other known consequences of altered
RAS activity and could also be the result of reduced
endothelial ACE2 expression caused by the SARS-
CoV-2 infection (reviewed in Najjar et al., 2020). Both
seizures and brain ischemia have been reported as neuro-
logical symptoms in critical COVID-19 patients.
Conclusions on the Role of Astrocytes and
Microglia in SARS-CoV-2 Infection
The accumulated knowledge on human and animal CoVs
supports the hypothesis that astroglia and microglia
could have a major role in neurological symptoms in
COVID-19 patients.
Glial Cells as SARS-CoV-2 Targets
Some clinical findings and extensive research on other
CoVs show that this possibility may exist, with infected
glial cells supporting productive infection or persisting as
nonproductive reservoirs of SARS-CoV-2 as observed
for animal CoVs (Figure 2). Astroglial-productive
SARS-CoV-2 infection is unlikely, since the destruction
of the astroglial network would have catastrophic effects
in the CNS, together with a massive proinflammatory
response due to cell death. On the other hand, the pro-
ductive infection of microglia would give rise to a focal
depletion of this highly heterogenic population of micro-
glial cells and exacerbated proinflammatory response.
The present clinical evidence of neurological symptoms
in SARS-CoV-2 patients does not fully support these
possibilities. Much more likely is that a nonproductive
glial infection, even in part of glial population (i.e., peri-
vascular), may turn astrocytes and microglia to a mild
proinflammatory phenotype, causing a malfunction of
astrocytes and disturbing microglial functions, with det-
rimental consequences for neuronal homeostasis and sur-
vival (Figure 2).
Figure 3. Microglia and Astrocytes as Effectors of Altered Brain RAS.
RAS-mediated proinflammatory priming: SARS-CoV-2 utilizes ACE2 as an entry route and reduces ACE2 availability and activity in endothelial
cells. Reduced ACE2 activity increases Ang II levels and consequently ATR1 activity in microglial cells that respond with activation of NF-jB
and proinflammatory gene expression. Astrocytes respond to proinflammatory microglial mediators expanding neuroinflammation and
neurodegeneration.
Reduced anti-inflammatory and antioxidant activity: Decreased ACE2 activity reduces Ang (1-7) concentration and MasR activity in astrocytes
and other cell types. Reactive oxygen species and proinflammatory mediators increase in CNS parenchyma and also in brain blood vessels.
Neuronal malfunction or even neuronal death may occur in this situation.
A¼ astrocytes; M¼microglia; N¼ neurons.
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Glial Cells as Proinflammatory Effectors
It is highly probable that glial cells have an important
role in initiating/expanding neuroinflammation in the
SARS-CoV-2-infected brain (Figure 2). This scenario
does not require that SARS-CoV-2 infects the CNS,
since endothelial cells may transfer the proinflammatory
signals from periphery to the CNS parenchyma activat-
ing the inflammatory response in microglia and astro-
cytes, worsening the clinical outcome and neurovirulence.
Glial Cells Involved in Brain RAS Alterations
SARS-CoV-2 and its predecessor SARS-CoV share the
unique feature that is the binding to ACE2. Astrocytes
are main players in brain RAS system, and microglia
respond to increased Ang II levels secreting proinflam-
matory cytokines (Figure 3). Thus, downregulation in
ACE2 level induced by SARS-CoV-2 could have detri-
mental effects both by reducing anti-inflammatory and
antiapoptotic Ang (1–7) effects, exacerbating ATR1-
dependent proinflammatory response and reducing
brain blood flow. This may have serious consequences,
not only for brain parenchyma but also for the whole
organism, due to the main role of brain RAS in regions
associated with cardiovascular control.
The present SARS-CoV-2 outbreak has taken the
world by surprise and has demanded for rapid implemen-
tation of measures that help contain the virus, while sci-
entists all over the world race against the pandemic to
find treatments. Taking into consideration the important
neurological clinical manifestations stated earlier, and
the role of the different CNS cell types, gaining as
much knowledge as possible from COVID-19 impact in
the nervous system is essential to improve future treat-
ment strategies and therapies.
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